Awaiting development: Guidance and quality standards

Showing 261 to 270 of 275

Guidance and quality standards awaiting development
Title	Type
Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]	Technology appraisal guidance
Vilobelimab for treating COVID 19 [TSID11815]	Technology appraisal guidance
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]	Technology appraisal guidance
WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467]	Technology appraisal guidance
Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity [TSID11902]	Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies [TSID10765]	Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable [TSID10477]	Technology appraisal guidance
Zanidatamab in combination for untreated HER2-positive unresectable advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma [ID6672]	Technology appraisal guidance
Zanubrutinib with rituximab for untreated mantle cell lymphoma when a stem cell transplant is unsuitable [ID6641]	Technology appraisal guidance
Zavegepant for treating acute migraine [TSID11998]	Technology appraisal guidance